The earnings call reflected a mix of positive outcomes, such as strong performance in certain product lines and progress on compliance efforts, but was overshadowed by significant revenue and EPS declines, a large goodwill impairment charge, and challenges in specific business segments.

Company Guidance

During the Integra LifeSciences Second Quarter 2025 Financial Results Call, the company provided guidance indicating a positive trajectory despite some ongoing challenges. For Q3, Integra anticipates revenue between $410 million and $420 million, reflecting 8% to 10% reported growth. The full-year revenue guidance was revised to a range of $1.655 billion to $1.68 billion, with expected organic growth between 0.6% and 2.1%. Adjusted earnings per share (EPS) guidance for Q3 is set between $0.40 and $0.45, while the full-year EPS guidance remains at $2.19 to $2.29. Key efforts include advancing the Compliance Master Plan, anticipating no new material shipholds for the rest of the year, and maintaining a strong focus on operational improvements and cost management. The company also expects minimum annualized savings of $25 million to $30 million over the next 12 to 18 months through strategic initiatives aimed at driving sustained margin expansion.

Strong Performance in Integra Skin

Achieved highest ever production levels in Q2 for Integra Skin, with expectations to maintain normal revenue run rate through the rest of the year. Double digit growth from DuraSorb and Integra Skin.

Completion of Compliance Master Plan Assessments

Completed assessments at all internal manufacturing sites ahead of schedule with no new related shipholds since last earnings call, supporting operational readiness.

Updated Financial Guidance

Total liquidity of $1.1 billion, updated full-year revenue guidance to a range of $1.655 billion to $1.68 billion, and maintaining full-year EPS guidance of $2.19 to $2.29.

Integra Lifesciences (IART) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IART Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.43 / -	0.41	―	―	―
Jul 31, 2025	2025 (Q2)	0.44 / 0.45	0.63	-28.57% (-0.18)
May 05, 2025	2025 (Q1)	0.43 / 0.41	0.55	-25.45% (-0.14)
Feb 25, 2025	2024 (Q4)	0.85 / 0.97	0.89	8.99% (+0.08)
Nov 04, 2024	2024 (Q3)	0.39 / 0.41	0.76	-46.05% (-0.35)
Jul 29, 2024	2024 (Q2)	0.62 / 0.63	0.71	-11.27% (-0.08)
May 06, 2024	2024 (Q1)	0.55 / 0.55	0.74	-25.68% (-0.19)
Feb 28, 2024	2023 (Q4)	0.90 / 0.89	0.94	-5.32% (-0.05)
Oct 25, 2023	2023 (Q3)	0.78 / 0.76	0.86	-11.63% (-0.10)
Jul 26, 2023	2023 (Q2)	0.57 / 0.71	0.82	-13.41% (-0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IART Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$12.37	$13.14	+6.22%
May 05, 2025	$16.85	$13.28	-21.19%
Feb 25, 2025	$22.05	$24.72	+12.11%
Nov 04, 2024	$19.28	$24.12	+25.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Integra Lifesciences Holdings Corp. (IART) report earnings?

Integra Lifesciences Holdings Corp. (IART) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is Integra Lifesciences Holdings Corp. (IART) earnings time?

Integra Lifesciences Holdings Corp. (IART) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IART EPS forecast?

IART EPS forecast for the fiscal quarter 2025 (Q3) is 0.44.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing